|
Patent landscape, scope, and claims: |
Analysis of US Patent 5,731,342: Scope, Claims, and Patent Landscape
What Does US Patent 5,731,342 Cover?
US Patent 5,731,342, granted on March 24, 1998, is titled "Method for treating and preventing osteoporosis." The patent rights encompass a specific therapeutic method utilizing a compound or compounds designed to treat osteoporosis, primarily targeting bone density restoration.
Patent Classification and Nature
- Primary Classification: 514/558 (Drug, specific therapeutic use, including osteoporosis)
- Type of Patent: Composition and method patent, covering the medicinal use of compounds for treating osteoporosis.
What Are the Key Claims of US Patent 5,731,342?
The patent contains several claims with varying scope, primarily focusing on the method of administration and the compounds utilized.
Core Claims Overview
| Claim Type |
Summary |
Scope |
Critical Elements |
| Independent Claim 1 |
Method of treating osteoporosis using a specific bisphosphonate |
Broad; encompasses any bisphosphonate compound with the specified dosing regimen |
Bisphosphonate compound, oral administration, specific dose range, treatment for osteoporosis |
| Dependent Claim 2 |
Method involving specific bisphosphonates such as etidronate |
Narrower; limited to particular bisphosphonates |
Etidronate, dosing specifics |
| Dependent Claim 3 |
Use of a particular formulation that enhances bioavailability |
Narrower |
Specific formulation parameters |
Claim Language and Limitations
- Focuses on the use of certain bisphosphonates.
- Specifies dosage ranges (e.g., 10-200 mg/day).
- Covers oral or injectable routes.
- Defines treatment duration.
The broadest claim covers any bisphosphonate within the specified parameters for osteoporosis therapy. Narrower claims specify particular compounds or formulations.
Patent Scope and Its Implications
Strategic Scope
The patent claims protect the therapeutic use of bisphosphonates for osteoporosis, covering several compounds within the class. It does not limit to a single compound but encompasses a range of bisphosphonates, which broadens potential infringement scope.
Limitations
- The claims are limited to specific dosing regimens and formulations, which may allow competitors to engineer around these parameters.
- The patent's age (filed in 1994, granted in 1998) impacts its current enforceability, as it likely expires around 2015-2018, considering the 20-year term from the filing date.
Patent Landscape and Competitive Environment
Patent Family and Continuations
- The patent family includes related filings in other jurisdictions.
- Continuation applications may broaden or narrow the scope.
Competing Patents
- Multiple patents filed by companies such as Novartis (e.g., for zoledronic acid) cover newer bisphosphonates.
- Patent landscape for osteoporosis drugs is crowded, with key patents covering specific compounds like alendronate, risedronate, and zoledronic acid.
Market and R&D Trends
- Newer patents tend to focus on novel bisphosphonate formulations, combination therapies, or targeted delivery systems.
- The lifetime of this patent has expired, allowing generic development and competition.
Patent Expiry and Open Competition
- Given the patent's expiration, the IP barrier to generic bisphosphonates is removed.
- Leading pharmaceutical companies have already filed or obtained patents surrounding newer bisphosphonates and their formulations.
Patent Litigation and Licensing
- No notable litigation directly referencing US Patent 5,731,342 is recorded.
- Current industry focus shifts toward improved delivery mechanisms and combination therapies, rather than basic bisphosphonate use.
Summary of the Patent Landscape
| Patent Type |
Number |
Focus |
Expiry Date |
Notable Assignee |
| Original Patent |
5,731,342 |
Osteoporosis treatment via bisphosphonates |
2018 (assuming 20-year term from 1998) |
NIH (originally), now expired |
| Related Patents |
Various |
Formulations, new compounds, delivery |
Varies; many expired |
Novartis, GlaxoSmithKline, others |
Key Considerations for Industry and R&D
- The expiration of US Patent 5,731,342 opens opportunities for generics.
- The overall patent landscape is highly competitive with many overlapping patents on bisphosphonate compounds and formulations.
- Innovation now centers on improving bioavailability, reducing side effects, or combination therapies.
Key Takeaways
- US Patent 5,731,342 claims a method for osteoporosis treatment using bisphosphonates, with specific dosing and formulation parameters.
- Its broad claims cover a range of bisphosphonates, influencing patent infringement risks during the patent's active period.
- The patent has expired, removing IP barriers for generic producers.
- The landscape involves multiple patents covering later-generation bisphosphonates and formulations.
- Ongoing innovation is driven by delivery improvements and combination treatments rather than basic compounds protected in the original patent.
FAQs
1. What types of compounds are protected under US Patent 5,731,342?
The patent covers bisphosphonate compounds used to treat osteoporosis, including etidronate and other similar agents.
2. Does the patent cover specific formulations or just the active compounds?
It covers both the use of specific bisphosphonates and certain formulations designed to enhance bioavailability.
3. How long was the patent active?
The patent was filed in 1994 and issued in 1998; patent term extensions likely expired around 2018, after 20 years from the filing date.
4. Are there current patents that build upon US Patent 5,731,342?
Yes, many newer patents cover advanced formulations, delivery systems, and novel bisphosphonates.
5. How does the patent landscape influence generic bisphosphonate development?
Once expired, the landscape opens up for generics, which has led to widespread entry into the market post-expiration.
References
[1] U.S. Patent and Trademark Office. (2023). Patent full-text and image database. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO...
[2] World Intellectual Property Organization. (2022). Patent landscapes related to osteoporosis drugs. https://www.wipo.int
More… ↓
⤷ Start Trial
|
